Dr. Ellingboe joined Innovimmune as Vice President of Discovery Sciences in 2015. He joins Innovimmune after several decades in various senior leadership roles at Pfizer (Wyeth Research), and more recently as Senior Vice President of Discovery Chemistry at GVK Biosciences, a life sciences CRO based in Hyderabad, India. At Pfizer (Wyeth Research), Dr. Ellingboe was Assistant Vice President of Medicinal Chemistry and was responsible for introducing library synthesis into the medicinal chemistry department, and for applying this technology to projects in all therapeutic areas. A number of clinical candidates resulted from this work including serotonin 5-HT6 modulators, a TACE inhibitor, and an MMP-13 inhibitor. He was then responsible for hit to lead activities in all therapeutic areas. Working closely with the HTS group and the therapeutic areas, his group developed approaches to quickly triaging hit sets and developing the most promising compounds into quality lead series. He also led efforts to develop a high-quality screening library for use by the HTS group. Finally, he led a medicinal chemistry group working on targets in Inflammation and Oncology that delivered a number of clinical candidates, including PI3K and mTOR inhibitors. More recently, he spent several years working for GVK Biosciences where he was responsible for directing medicinal chemistry efforts in a variety of discovery programs. Dr. Ellingboe is an author of more than 100 peer-reviewed journal articles, book chapters and presentations. He obtained his Ph.D. in Organic Chemistry at the Massachusetts Institute of Technology.